View Older Stories View More Recent Stories

Mar 23, 2022 01:00PM Clint Carnell Named CEO of InBrace
Mar 9, 2022 07:00AM Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
Feb 14, 2022 05:26PM Form 13F-HR venBio Partners LLC For: Dec 31
Feb 14, 2022 02:33PM Form SC 13G/A Metacrine, Inc. Filed by: venBio Global Strategic Fund, L.P.
Feb 14, 2022 02:31PM Form SC 13G/A Harmony Biosciences Hold Filed by: venBio Global Strategic Fund II L.P.
Feb 2, 2022 03:00AM NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease
Jan 20, 2022 05:00AM ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Jan 19, 2022 07:00AM Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
Jan 11, 2022 04:47PM Form SC 13G CinCor Pharma, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Dec 29, 2021 11:29AM Form D OCA venBio IV LLC
Dec 17, 2021 07:00AM NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
Nov 29, 2021 01:00PM Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market
Nov 16, 2021 05:00AM ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
Nov 16, 2021 03:02AM Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity
Nov 15, 2021 04:46PM Form 13F-HR venBio Partners LLC For: Sep 30
Nov 4, 2021 04:18PM Form SC 13D Ventyx Biosciences, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Oct 27, 2021 04:10PM PPD Reports Third Quarter and Year-To-Date 2021 Results
Oct 26, 2021 04:35PM Form 4 Metacrine, Inc. For: Oct 22 Filed by: venBio Global Strategic Fund, L.P.
Oct 25, 2021 07:41PM Form 4 Ventyx Biosciences, Inc. For: Oct 25 Filed by: venBio Global Strategic Fund III, L.P.
Oct 20, 2021 06:46PM Form 3 Ventyx Biosciences, Inc. For: Oct 20 Filed by: venBio Global Strategic Fund III, L.P.
Oct 19, 2021 10:00AM HistoWiz Raises $32M Series A Financing
Oct 18, 2021 08:00AM NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases
Oct 12, 2021 08:00AM CinCor Pharma Raises $143 Million in Series B Financing
Oct 5, 2021 08:00AM HTG Expands Therapeutics Team
Sep 20, 2021 05:00AM Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round
Sep 8, 2021 08:05AM InBrace Raises $102M Series D Financing
Sep 8, 2021 07:00AM Attralus Closes $116 Million Series B Financing
Aug 26, 2021 06:30AM Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
Aug 16, 2021 04:44PM Form 13F-HR venBio Partners LLC For: Jun 30
Jul 28, 2021 04:11PM PPD Reports Second Quarter and Year-To-Date 2021 Results
Jul 9, 2021 04:02PM Form SC 13D Elevation Oncology, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Jun 24, 2021 06:04PM Form 3 Elevation Oncology, Inc. For: Jun 24 Filed by: venBio Global Strategic Fund III, L.P.
Jun 15, 2021 08:00AM RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
Jun 3, 2021 08:00AM venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences
May 17, 2021 04:26PM Form 13F-HR venBio Partners LLC For: Mar 31
May 14, 2021 05:26PM Form D venBio Global Strategic
May 10, 2021 07:00AM Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
May 7, 2021 04:13PM Form SC 13D/A Akero Therapeutics, Inc. Filed by: venBio Global Strategic Fund II L.P.
May 7, 2021 01:01PM Form SC 13G IMPEL NEUROPHARMA INC Filed by: venBio Global Strategic Fund II L.P.
Apr 29, 2021 06:44PM Form 4 IMPEL NEUROPHARMA INC For: Apr 27 Filed by: venBio Global Strategic Fund II L.P.
Apr 29, 2021 04:15PM Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
Apr 29, 2021 04:15PM Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
Apr 27, 2021 04:13PM PPD Reports First Quarter 2021 Results
Apr 26, 2021 07:11PM Form 4 IMPEL NEUROPHARMA INC For: Apr 22 Filed by: venBio Global Strategic Fund II L.P.
Mar 16, 2021 08:00AM Ventyx Biosciences Doses First Subject in a Phase 1 Trial of VTX-958, a Selective Allosteric TYK2 Inhibitor for Autoimmune Diseases
Mar 9, 2021 09:09AM New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million
Mar 9, 2021 08:00AM Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs
Mar 1, 2021 07:00AM FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
Feb 26, 2021 07:00AM Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
Feb 23, 2021 04:05PM PPD Reports Fourth Quarter and Full Year 2020 Results
View More Recent Stories View Older Stories